GlaxoSmithKline (LON:GSK) had its target price reduced by research analysts at Goldman Sachs Group from GBX 2,060 ($25.35) to GBX 2,020 ($24.86) in a research report issued on Friday, Borsen Zeitung reports. The brokerage currently has a “buy” rating on the stock. Goldman Sachs Group’s price target points to a potential upside of 32.04% from the stock’s current price.
Several other equities analysts have also recently weighed in on the company. Citigroup reiterated a “neutral” rating on shares of GlaxoSmithKline in a research report on Wednesday, July 15th. Credit Suisse Group dropped their price objective on GlaxoSmithKline from GBX 1,860 ($22.89) to GBX 1,700 ($20.92) and set a “neutral” rating for the company in a research note on Thursday. Liberum Capital reissued a “hold” rating on shares of GlaxoSmithKline in a research note on Thursday, May 28th. Oddo Bhf reissued a “neutral” rating and set a GBX 1,840 ($22.64) price objective on shares of GlaxoSmithKline in a research note on Monday, June 22nd. Finally, Oddo Securities lifted their price objective on GlaxoSmithKline from GBX 1,760 ($21.66) to GBX 1,840 ($22.64) and gave the company a “neutral” rating in a research note on Monday, June 22nd. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of GBX 1,832.24 ($22.55).
Shares of LON GSK opened at GBX 1,529.80 ($18.83) on Friday. The stock has a market cap of $76.75 billion and a PE ratio of 14.30. GlaxoSmithKline has a fifty-two week low of GBX 16.27 ($0.20) and a fifty-two week high of GBX 1,857 ($22.85). The company has a debt-to-equity ratio of 159.26, a quick ratio of 0.54 and a current ratio of 0.87. The stock has a fifty day moving average of GBX 1,624 and a 200-day moving average of GBX 1,636.23.
GlaxoSmithKline (LON:GSK) last announced its quarterly earnings results on Wednesday, July 29th. The company reported GBX 56.90 ($0.70) earnings per share for the quarter. On average, sell-side analysts predict that GlaxoSmithKline will post 11385.0001492 EPS for the current year.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Read More: What Factors Can Affect Return on Equity?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.